Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
ESMO 2024 – a role for immunotherapy in ovarian cancer
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
